Viridian Therapeutics Q1: THRIVE TED trial enrollment completed (113 pts); topline data Sept 2024

Viridian Therapeutics, Inc.\DE

Cash, cash equivalents, and short-term investments of $613.2M as of March 31, 2024, sufficient into H2 2026.
Net loss of $48.5M for Q1 2024, compared to $68.2M in Q1 2023.
THRIVE global phase 3 trial in active TED enrolled 113 patients (exceeded target of 90); topline data expected September 2024.
Positive FDA Type C meeting for VRDN-003 subcutaneous candidate; pivotal program on track to start mid-2024.
VRDN-006 FcRn inhibitor IND submission on track for year-end 2024; VRDN-008 NHP data expected H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Viridian Therapeutics, Inc.\DE reported first quarter ended March 31, 2024 results: net income $48.5 million.

Period: first quarter ended March 31, 2024
Net income: $48.5 million
Result: reported results

Exact text from the filing

The company’s net loss was $48.5 million for the first quarter ended March 31, 2024

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Viridian Therapeutics, Inc.\DE filing history →

Source: SEC EDGAR

accession 0001193125-24-133770

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.